BiondVax
 | This article contains promotional content. (August 2023) |
 |
 | |
| Company type | Public |
|---|---|
| Nasdaq: BVXV | |
| Industry | Pharmaceuticals |
| Founded | 2003 |
| Headquarters | , |
Number of employees | 30 (2022) |
| Website | www |
BiondVax Pharmaceuticals Ltd. is an Israeli biopharmaceutical company focused on developing, and manufacturing immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases.
In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, BiondVax is developing nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.
History
Since its founding, BiondVax has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and it built, owns and operates a biologics manufacturing facility housing its laboratories, production facilities and offices.
In December 2021, BiondVax signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences– and the UMG to enter a strategic collaboration for the development and commercialization of COVID-19 NanoAbs.